Clinical trial

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2022-08-16

PhaseN/A

Study timeline

Study start (actual)2022-08-16Date precision: day

Registry last updated2026-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Obstructive Hypertrophic Cardiomyopathyunresolved

Interventions

MavacamtenDRUG · verified · RxNorm: mavacamten

Non-mavacamten symptomatic oHCM therapyDRUG

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

New YorkNew York, United States2 HoustonTexas, United States2 BostonMassachusetts, United States2 DallasTexas, United States2 BaltimoreMaryland, United States2 NashvilleTennessee, United States2 MadridSpain2 ClevelandOhio, United States2 IndianapolisIndiana, United States2 Kansas CityMissouri, United States2 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05489705 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.